All In Biotech

Drug Trial Radar · NCT00355862

Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Jul 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 525 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

525

Actual

Start

Jan 2006

Primary completion

Apr 2009

Study completion May 2014

Sponsor

Lead sponsor
University of RegensburgAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC recurrence-free patient survival.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)Drug

    center specific therapeutic regimen without mTOR inhibition

  • SirolimusDrug

    Sirolimus based immunosuppression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence free survivalTime frame: 5 year follow up after last patient in

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Regensburg University

    Regensburg, Bavaria, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.